Your browser doesn't support javascript.
GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches.
Lang, Frederick M; Lee, Kevin M-C; Teijaro, John R; Becher, Burkhard; Hamilton, John A.
  • Lang FM; Roivant Sciences Inc., New York, NY, USA.
  • Lee KM; Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, Melbourne, Victoria, Australia.
  • Teijaro JR; Department of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA, USA.
  • Becher B; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Hamilton JA; Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, Melbourne, Victoria, Australia. jahami@unimelb.edu.au.
Nat Rev Immunol ; 20(8): 507-514, 2020 08.
Article in English | MEDLINE | ID: covidwho-613021
ABSTRACT
Therapeutics against coronavirus disease 2019 (COVID-19) are urgently needed. Granulocyte-macrophage colony-stimulating factor (GM-CSF), a myelopoietic growth factor and pro-inflammatory cytokine, plays a critical role in alveolar macrophage homeostasis, lung inflammation and immunological disease. Both administration and inhibition of GM-CSF are currently being therapeutically tested in COVID-19 clinical trials. This Perspective discusses the pleiotropic biology of GM-CSF and the scientific merits behind these contrasting approaches.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Granulocyte-Macrophage Colony-Stimulating Factor / Coronavirus Infections / Betacoronavirus Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Nat Rev Immunol Journal subject: Allergy and Immunology Year: 2020 Document Type: Article Affiliation country: S41577-020-0357-7

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Granulocyte-Macrophage Colony-Stimulating Factor / Coronavirus Infections / Betacoronavirus Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Nat Rev Immunol Journal subject: Allergy and Immunology Year: 2020 Document Type: Article Affiliation country: S41577-020-0357-7